Our Current Trials

Condition Trial Name Sponsor
Solid 1403-0002: MDM2 Inhibitor BI 907828 and Anti PD-1 Antibody Ezabenlimab in Select Solid Tumors Boehringer Ingelheim
Solid Tumors 1719-001: MRTX1719 in MTAP Deleted Advanced Solid Tumors Mirati Therapeutics, Inc.
Rectal Cancer 19-288: Neoadjuvant TSR-042 (dostarlimab) for Patients with Rectal Adenocarcinoma Memorial Sloan Kettering Cancer Center
Breast Cancer ASCENT-03: Sacituzumab Govitecan as First Line Treatment for Patients With Triple Negative Breast Cancer Gilead Sciences
Breast Cancer ASCENT-04: Sacituzumab Govitecan in Combination With Pembrolizumab as First Line Treatment for Patients With PD-L1 Expressing Triple Negative Breast Cancer Gilead Sciences
Cachexia in Colorectal or Pancreatic Cancer AV-380-22-102: Study of GDF-15 Inhibitor AV-380 for the Treatment of Cachexia in Patients with Metastatic Colorectal or Pancreatic Cancer Receiving First Line Chemotherapy AVEO Pharmaceuticals, Inc.
Solid Tumors BI 1403-0001: MDM2 inhibitor BI 907828 in MDM2 Amplified Advanced Solid Tumors Boehringer Ingelheim
Non-Small Cell Lung Cancer BI 1479-0001: Anti-HER2 TKI BI 1810631 for the Treatment of HER2 Mutant NSCLC Boehringer Ingelheim
Breast Cancer BRI-ROL-001: SV-BR-1-GM Regimen in Combination With Retifanlimab in Patients With Metastatic or Locally Recurrent Breast Cancer Who Have Failed Standard Therapy BriaCell Therapeutics Corporation
Dedifferentiated Liposarcoma Brightline-1: MDM2 Inhibitor BI 907828 for the First Line Treatment of MDM2-Mutant Advanced or Metastatic Dedifferentiated Liposarcoma Boehringer Ingelheim
Biliary Tract Cancer, Pancreatic Cancer Brightline-2: MDM2 Inhibitor BI 907828 in MDM2 amplified, TP53 Wild Type Pancreatic or Biliary Tract Cancer Boehringer Ingelheim
Breast Cancer CDK2/4/6 Inhibitor RGT-419B in HR-Positive, HER2-Negative Metastatic Breast Cancer Regor Pharmaceuticals, Inc.
Solid Tumor or Lymphoma CS5001-101: A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas CStone Pharmaceuticals
Solid Tumors DAY101-102: Pan-RAF Inhibitor DAY101 for Patients with Relapsed/Refractory MAPK-Altered Solid Tumors Day One Biopharmaceuticals, Inc.
Breast Cancer DESTINY-Breast09: Trastuzumab deruxtecan for First Line Treatment of Advanced/Metastatic HER2-Positive Breast Cancer AstraZeneca
Solid Tumors ENV-ONC-101: Hedgehog Pathway Inhibitor in Patients with Advanced Solid Tumors Harboring PTCH1 Loss of Function MutationsTaladegib Endeavor Biomedicines, Inc.
Central Nervous System Cancer F8294-201b: BRAF Inhibitor FORE8394 in Recurrent/Refractory BRAF V600E Mutant CNS Malignancy Fore Biotherapeutics
Solid Tumors F8394-201a: BRAF Inhibitor FORE8394 for the Treatment of BRAF Fusion Positive Advanced Solid Tumors Fore Biotherapeutics
Colon or Rectal Cancer GO-010: Neoantigen Vaccine GRT-C901/GRT-R902 as Maintenance After First Line Metastatic Therapy Gritstone bio, Inc.
Head and Neck Squamous Cell Carcinoma GS-US-548-5916: Magrolimab Combinations in Recurrent or Metastatic HNSCC Gilead Sciences, Inc.
Non-Small Cell Lung Cancer HARMONIC: A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma Lantern Pharma Inc.
Colon or Rectal Cancer KRYSTAL-10: Adagrasib in KRAS G12C Mutated Colorectal Cancer Mirati Therapeutics, Inc.
Solid Tumors KRYSTAL-1: Multiple Cohort Study of Adagrasib Monotherapy or Combinations for Patients With KRAS G12C Mutant Solid Tumors Mirati Therapeutics Inc.
Non-Small Cell Lung Cancer KRYSTAL-7: Adagrasib Monotherapy or in Combination With Pembrolizumab as First Line Treatment for KRAS G12C Mutant NSCLC Mirati Therapeutics Inc.
Diffuse Large B-Cell Lymphoma LOTIS-9: Loncastuximab Tesirine and Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Patients ADC Therapeutics SA
Colon or Rectal Cancer LUT014 Gel for EGFR-Inhibitor Induced Acneiform Rash Lutris Pharma Ltd.
Solid Tumors MANTRA-2: Milademetan for the Treatment of MDM2 Amplified Solid Tumors Rain Oncology Inc
Non-Hodgkin Lymphoma MorningSun: Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies Genentech, Inc.
Hyperkalemia/Chronic Kidney Disease NYH-01: Hyperkalemia/Chronic Kidney Disease Relypsa
Solid Tumors OnTARGET: Crofelemer for Diarrhea Prophylaxis in Patients Receiving Targeted Therapy Napo Pharmaceuticals
Solid Tumors PBI-200-101: TRK Inhibitor PBI-200 in NTRK Fusion Positive or NTRK Amplified Solid Tumor Pyramid Biosciences
Colorectal Cancer PORCUPINE: PORCN Inhibitor RXC004 Alone or in Combination with Nivolumab for Microsatellite Stable RNF43 or RSPO Altered Metastatic Colorectal Cancer Redx Pharma Plc
Solid Tumors PRECISION 1: Nab-Sirolimus for the Treatment of Patients With TSC1/2 Mutant Advanced or Metastatic Solid Tumor Aadi Bioscience, Inc.
Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome PRT1419-03: PRT1419 in Patients with Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or Myelodysplastic Syndrome Prelude Therapeutics
Solid Tumors REFOCUS: RLY-4408 in FGFR2-Altered Solid Tumors Relay Therapeutics
Breast Cancer SERENA-6: AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression AstraZeneca
Solid Tumors SPARTA: c-MET Inhibitor APL-101 for Patients with c-MET Altered Solid Tumors Apollomics Inc.
Multiple Myeloma TAK-573-2001: Modakafusp alfa in Combination with Daratumumab for the Treatment of Relapsed/Refractory Multiple Myeloma Takeda Development Center Americas, Inc
Solid Tumors TAPISTRY: Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You Platform Study Hoffmann-La Roche
Breast Cancer [Registry] Liquid vs Tissue Biopsy Concordance in Samples of 1st Suspected Breast Cancer Recurrence & Metastasis Epic Sciences
Cancer Diagnosis [Registry] MSK-IMPACT/ACCESS Genomic Profiling in Cancer Patients Memorial Sloan Kettering Cancer Center
Various Indications [Sample Collection] Clinical Biospecimen Procurement Protocol to Support Advancements in Medical Diagnoses of Diseases (PROMEDx) Precision for Medicine
Solid Tumors [Sample Collection] Collection and Distribution of Biofluids for Research Purposes Bluestar Genomics
Solid Tumors [Sample Collection] Detecting cancers Earlier Through Elective plasma-based Cancer SEEK Testing (DETECT-ASCEND 2) Exact Sciences Thrive LLC
Various Indications [Sample Collection] Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized Management of Patients (MTG-022) MT Group
Various Indications [Sample Collection] Prospective Collection of Samples for Research (SERATRIALS-05035) SERATRIALS, LLC.
Solid Tumors [Sample Collection] Vallania: A Case Control Study for the Development of Multiomics Blood Tests for Cancer Screening Freenome Holdings Inc.
Solid Tumors eNRGy: HER2xHER3 Bispecific Antibody MCLA-128 for the Treatment of an Advanced or Metastatic Solid Tumor Malignancy With a Documented NRG1 Fusion Merus N.V.